Weina Zhu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Weina Zhu has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Hua Liang
Department of Clinical Laboratory, The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, 330006, China
2 shared publications - Juxiang Li
Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
2 shared publications - Miangliang Qiu
Department of Rheumatology, The Affiliated Hospital of Jiangxi University of Chinese Medicine, China
2 shared publications - Mo Lisha
The Affiliated Hospital of Jiangxi University of Chinese Medicine, China
2 shared publications - Weidong Xu
Department of Rheumatology, The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, 330006, China.
2 shared publications - Xiangjuan Zheng
School of Chemistry and Chemical Engineering, Nanchang University, Nanchang 330031, China
2 shared publications
Latest Publications
- Open Access
- 31 July 2020
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (31) , e21447
Fourteen small molecule and biological agents for psoriatic arthritis
Background: The comparative efficacy and safety of small molecule and biological agents in the treatment of psoriatic arthritis (PsA) remain unknown. Objectives: To compare the efficacy and safety of 14 small molecule and biological agents by network meta-analysis (NMA). Methods: Relevant randomized controlled trials involving biological treatments for PsA were identified by searching PubMed, Cochrane Library, EMBASE, Web of Science, and Clinicaltrials.gov and by manual retrieval, up to June 2018. NMA was conducted with Stata 14.0 based on the frequentist method. Effect measures were odds ratios (ORs) with 95% confidence intervals (CIs). Intervention efficacy and safety were ranked according to the surface under the cumulative ranking curve (SUCRA). Results: A total of 30 studies involving 10,191 adult subjects were included. According to NMA, ≥ 20% improvement in modifed American College of Rheumatology response criteria (ACR20) response, Psoriasis Area and Severity Index 75 (PASI75) response, and serious adverse events rate (SAEs) were observed. In direct comparisons, most of the biologics performed better than placebo in terms of ACR20 response rate and PASI75 response rate. Additionally, all medicines were comparable to placebo in terms of SAEs except secukinumab. In terms of mixed comparisons, with regard to the ACR20 response, etanercept (ETN) and infliximab (IFX) were more effective than golimumab (GOL), with ORs of 3.33 (95% CI: 1.17–9.48) and 1.24 (95% CI: 0.61–2.52), respectively. For PASI75 response, IFX was superior to certolizumab pegol (OR = 10.08, 95% CI: 1.54–75.48). In addition, these medicines were comparable to each other in terms of SAEs. ETN and IFX were shown to have the most favorable SUCRA for achieving improved ACR20 and PASI75 responses, respectively, while ABT-122 exhibited the best safety according to the SUCRA for SAEs. Considering both the efficacy (ACR20, PASI75) and safety (SAEs), GOL, ETN, and IFX are the top 3 treatments. Conclusions and Implications: Direct and indirect comparisons and integrated results suggested that the 3 anti- tumor necrosis factor -α biologics (GOL, ETN, and IFX) can be considered the best treatments for PsA after comprehensive consideration of efficacy and safety.
- 31 July 2020
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (31) , e21447
Open AccessFourteen small molecule and biological agents for psoriatic arthritis
Background: The comparative efficacy and safety of small molecule and biological agents in the treatment of psoriatic arthritis (PsA) remain unknown. Objectives: To compare the efficacy and safety of 14 small molecule and biological agents by network meta-analysis (NMA). Methods: Relevant randomized controlled trials involving biological treatments for PsA were identified by searching PubMed, Cochrane Library, EMBASE, Web of Science, and Clinicaltrials.gov and by manual retrieval, up to June 2018. NMA was conducted with Stata 14.0 based on the frequentist method. Effect measures were odds ratios (ORs) with 95% confidence intervals (CIs). Intervention efficacy and safety were ranked according to the surface under the cumulative ranking curve (SUCRA). Results: A total of 30 studies involving 10,191 adult subjects were included. According to NMA, ≥ 20% improvement in modifed American College of Rheumatology response criteria (ACR20) response, Psoriasis Area and Severity Index 75 (PASI75) response, and serious adverse events rate (SAEs) were observed. In direct comparisons, most of the biologics performed better than placebo in terms of ACR20 response rate and PASI75 response rate. Additionally, all medicines were comparable to placebo in terms of SAEs except secukinumab. In terms of mixed comparisons, with regard to the ACR20 response, etanercept (ETN) and infliximab (IFX) were more effective than golimumab (GOL), with ORs of 3.33 (95% CI: 1.17–9.48) and 1.24 (95% CI: 0.61–2.52), respectively. For PASI75 response, IFX was superior to certolizumab pegol (OR = 10.08, 95% CI: 1.54–75.48). In addition, these medicines were comparable to each other in terms of SAEs. ETN and IFX were shown to have the most favorable SUCRA for achieving improved ACR20 and PASI75 responses, respectively, while ABT-122 exhibited the best safety according to the SUCRA for SAEs. Considering both the efficacy (ACR20, PASI75) and safety (SAEs), GOL, ETN, and IFX are the top 3 treatments. Conclusions and Implications: Direct and indirect comparisons and integrated results suggested that the 3 anti- tumor necrosis factor -α biologics (GOL, ETN, and IFX) can be considered the best treatments for PsA after comprehensive consideration of efficacy and safety.
- 16 January 2020
- Published by Springer Nature in Clinical Rheumatology
- Vol. 39 (3) , 967
Correction to: Effects of miR-150-5p on the growth and SOCS1 expression of rheumatoid arthritis synovial fibroblasts
The first name of the co-author of the above article was presented incorrect in the published version. The author name “Miangliang Qiu” should
- 16 January 2020
- Published by Springer Nature in Clinical Rheumatology
- Vol. 39 (3) , 967
Correction to: Effects of miR-150-5p on the growth and SOCS1 expression of rheumatoid arthritis synovial fibroblasts
The first name of the co-author of the above article was presented incorrect in the published version. The author name “Miangliang Qiu” should
- 26 December 2019
- Published by Springer Nature in Clinical Rheumatology
- Vol. 39 (3) , 909-917
Effects of miR-150-5p on the growth and SOCS1 expression of rheumatoid arthritis synovial fibroblasts
Objective miR-150-5p has been implicated in the regulation and onset of immune diseases. We investigated the effects of miR-150-5p on the functions of RA synovial fibroblasts (RASFs). Method The binding site between suppressor of cytokine signaling 1 (SOCS1) and miR-150-5p was analyzed using European Bioinformatics Institute database, and the 3′ UTR of SOCS1 mRNA, including the binding site, was amplified and ligated to the 3′-end of LUC2 gene in the pmirGL0 dual-luciferase vector. The pmirGL0 vector and corresponding mimics were subsequently co-transfected into 293T cells to compare the relative fluorescence intensity of LUC2 between the miR-150-5p mimics and the negative control (NC) mimics groups. Further, the RASF cell line MH7A was transfected with miR-150-5p or NC mimics and subjected to flow cytometric analysis, cell counting kit-8 assay, western blot analysis, qPCR, and enzyme-linked immunosorbent (ELISA) assay 48 h after transfection. Results miR-150-5p mimics resulted in a lower cell apoptotic rate and proportion of cells in the S phase. Using a dual-luciferase reporter gene assay, we then found that SOCS1 is a potential target of miR-150-5p. Compared with NC mimics, miR-150-5p mimics significantly decreased the protein and mRNA expression levels of SOCS1. ELISA assay showed that miR-150-5p mimics increased interleukin-6 level in the cell culture medium but did not influence tumor necrosis factor-alpha levels. Conclusions Overall, the growth-promoting effect of miR-150-5p on MH7A cells may be attributed to the miR-150-5p-induced degradation of SOCS1 mRNA, suggesting a potential therapeutic target for RA. Key Points • SOCS1 is a potential target of miR-150-5p. • miR-150-5p promoted the growth of RASF cell line MH7A. • miR-150-5p increased the secretion of IL-6 but did not significantly affect TNF-α levels in MH7A cells.
- 26 December 2019
- Published by Springer Nature in Clinical Rheumatology
- Vol. 39 (3) , 909-917
Effects of miR-150-5p on the growth and SOCS1 expression of rheumatoid arthritis synovial fibroblasts
Objective miR-150-5p has been implicated in the regulation and onset of immune diseases. We investigated the effects of miR-150-5p on the functions of RA synovial fibroblasts (RASFs). Method The binding site between suppressor of cytokine signaling 1 (SOCS1) and miR-150-5p was analyzed using European Bioinformatics Institute database, and the 3′ UTR of SOCS1 mRNA, including the binding site, was amplified and ligated to the 3′-end of LUC2 gene in the pmirGL0 dual-luciferase vector. The pmirGL0 vector and corresponding mimics were subsequently co-transfected into 293T cells to compare the relative fluorescence intensity of LUC2 between the miR-150-5p mimics and the negative control (NC) mimics groups. Further, the RASF cell line MH7A was transfected with miR-150-5p or NC mimics and subjected to flow cytometric analysis, cell counting kit-8 assay, western blot analysis, qPCR, and enzyme-linked immunosorbent (ELISA) assay 48 h after transfection. Results miR-150-5p mimics resulted in a lower cell apoptotic rate and proportion of cells in the S phase. Using a dual-luciferase reporter gene assay, we then found that SOCS1 is a potential target of miR-150-5p. Compared with NC mimics, miR-150-5p mimics significantly decreased the protein and mRNA expression levels of SOCS1. ELISA assay showed that miR-150-5p mimics increased interleukin-6 level in the cell culture medium but did not influence tumor necrosis factor-alpha levels. Conclusions Overall, the growth-promoting effect of miR-150-5p on MH7A cells may be attributed to the miR-150-5p-induced degradation of SOCS1 mRNA, suggesting a potential therapeutic target for RA. Key Points • SOCS1 is a potential target of miR-150-5p. • miR-150-5p promoted the growth of RASF cell line MH7A. • miR-150-5p increased the secretion of IL-6 but did not significantly affect TNF-α levels in MH7A cells.